Why the study?
Does acetazolamide reduce the severity of paralysis and alter serum insulin, glucose, and potassium levels in patients with familial periodic hypokalemic paralysis?
Does acetazolamide reduce the severity of paralysis and alter serum insulin, glucose, and potassium levels in patients with familial periodic hypokalemic paralysis?
Acetazolamide reduces the severity of paralytic attacks and lowers serum insulin and glucose levels in familial periodic hypokalemic paralysis, suggesting an indirect prophylactic action possibly via reduced absorption.
Answers are grounded in this paper and cite their sources.
May support acetazolamide prophylaxis in hypokalemic periodic paralysis; hypothesis-generating and requires randomized confirmation.
In four patients with periodic hypokalemic paralysis paralytic attacks were induced in the untreated state and later, after the patients had been treated with acetazolamide. There was a distinct, clinically favourable effect of acetazolamide upon the length as well as the severity of paralysis. The maximum fall in serum potassium was less marked during acetazolamide therapy. After treatment all four patients showed significantly reduced serum levels of glucose and insulin during induced attacks of paralysis as compared with the levels obtained during paretic attacks in the untreated state. These findings indicate that the prophylactic effect of this drug does not relate merely to metabolic acidosis. The hypothesis is advanced that the lower serum insulin and glucose levels might represent reduced absorption which would amount to an indirect prophylactic action.
No takes yet. Share an insight, caveat, or question.
Torsten Johnsen (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: